Increased levels of low-density lipoprotein cholesterol (LDL-C) are recognized as a primary
risk factor for atherosclerotic cardiovascular disease, which remains the leading cause of …

Statins inhibit the 3-hydroxy-3-methylglutaryl-CoA reductase enzyme and are the most
widely used medication for hypercholesterolemia. Previous studies on the metabolite …

Purpose Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are novel drugs
that have proven efficacy in improving cardiovascular outcomes. Roles for the PCSK9 …

Objectives We aimed to review whether PM and DM patients have an increased
cardiovascular (CV) risk, including ischaemic heart disease (IHD), cerebrovascular …

Abstract Purpose of Review To provide a systematic approach to management of the patient
with statin-attributed muscle symptoms. Recent Findings We examined the prevalence of …

Proprotein convertase subtilisin/kexin type 9 inhibition aft... : Current Opinion in Lipidology
Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior …

Cardiovascular diseases cause considerable health and economic burden, as they are the
leading cause of disability and death in the western world. Inactivity, hypertension, obesity …

Background: The use of aspirin for primary prevention of cardiovascular events in men and
women remains controversial. Our study aimed to investigate the role of aspirin in primary …

OBJECTIVE To assess lifetime cardiovascular disease (CVD) risk by coronary artery calcium
(CAC) score in individuals with diabetes from the Multi-Ethnic Study of Atherosclerosis …

While recent decades have seen substantial reductions in cardiovascular mortality, heart
disease remains the number one cause of death both in the United States and globally. This …